Meridian Bioscience OverviewTrack Meridian Bioscience's EBIT ($26M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Dec 31, 2022
Trailing 12 months ending Dec 31, 2022
As of the most recent data (December 2022), VIVO shows a EBIT of $26M. That compares with $84M in the prior-year period — down 68.8% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, VIVO's EBIT is now $26M (was $84M) — a 68.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Meridian Bioscience is outperforming or lagging.
The Healthcare sector average EBIT is about $23B. Meridian Bioscience is at $26M, which is lower that average. That is roughly 99.9% below the sector mean. Use the comparison chart on this page to see how VIVO stacks up against individual peers as well.
Tracking VIVO's ebit over time shows whether Meridian Bioscience is scaling, shrinking, or reshaping that part of the business. The current reading is $26M That compares with $84M in the prior-year period — down 68.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Meridian Bioscience's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $26M) with ownership activity and broader fundamentals.
